ng with HIV from your Dominican Republic and Tanzania. PLoS One 2020; 15:e0234666. 28. Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine in excess of 48 weeks. AIDS Behav 2020; 24:3533544. 29. Collins LF, Corbin-Johnson D, Asrat M, et al. Implementation of long-acting injectable cabotegravir-rilpivirine for HIV-1 remedy at a Ryan White-funding Clinic within the U.S. South. IDWeek, Virtual, 29 September October 2021. 30. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral 5-LOX Formulation prophylaxis for HIV prevention in heterosexual males and women. N Engl J Med 2012; 367:39910. 31. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who’ve sex with men. N Engl J Med 2010; 363:2587599. 32. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV preexposure prophylaxis (Learn): key success from a randomised, double-blind, multicentre, active-controlled, phase 3, noninferiority trial. Lancet 2020; 396:23954. 33. Andrews CD, Spreen WR, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 2014; 343:1151154.co-hivandaidsVolume 17 Amount one JanuaryA new paradigm for antiretroviral delivery Bares and Scarsi34. Dobard C, Makarova N, Nishiura K, et al. Long-acting cabotegravir protects macaques against repeated penile simian-human immunodeficiency virus exposures. J Infect Dis 2020; 222:39195. 35. Landovitz RJ, Li S, Eron JJ Jr, et al. Tail-phase security, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary examination of the HPTN 077 trial. Lancet HIV 2020; seven:e472 481. This evaluation of the pharmacokinetic tail (or drug decay) of long-acting CAB inside the HPTN-077 research describes the duration of drug detection soon after long-acting CAB discontinuation, also since the influence of sex and BMI on prolonged publicity through the tail phase. 36. Markowitz M, Frank I, Grant RM, et al. Security and tolerability of long-acting cabotegravir injections in HIV-uninfected guys (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV 2017; 4:e331 340. 37. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender males and transgender girls. N Engl J Med 2021; 385:59508. Principal examination from the HPTN-084 trial, which was a HDAC6 Accession double-blind trial to compared the efficacy and security of long-acting CAB versus oral tenofovir isoproxil fumarate mtricitabine as preexposure prophylaxis (PrEP) for MSM or transgender gals who’ve intercourse with guys. The study was stopped early for efficacy just after assessment of final results in the very first preplanned interim end-point evaluation because of fewer incident infections within the long-acting CAB group compared together with the oral PrEP group. 38. Delany-Moretlwe S, Hughes JP, Bock P, et al. Lengthy acting injectable cabote gravir is secure and powerful in stopping HIV infection in cisgender females: interim outcomes from HPTN 084. HIVR4P (HIV Exploration for Prevention) Virtual, 278 January and 3 February 2021. Abstract HY01.02. Key examination on the HPTN-083 trial, which was a double-blind trial to compared the efficacy and security of long-acting CAB versus oral tenofovir isoproxil fumarate mtricitabine as PrEP in cisgender females. The research was stopped early for effic